About Castleman Disease

Overview and Types

If you have been diagnosed with Castleman disease or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start.

- What Is Castleman Disease?

Key Statistics

Castleman disease is rare. Learn which form tends to be more common.

- Key Statistics for Castleman Disease
- What's New in Castleman Disease Research?

What Is Castleman Disease?

Castleman disease (CD) is a rare disease of lymph nodes and related tissues.It was first described by Dr. Benjamin Castleman in the 1950s. It is also known as Castleman's disease,giant lymph node hyperplasia, and angiofollicular lymph node hyperplasia (AFH). CD is not cancer. Instead, it is called a **lymphoproliferative disorder**. This meansthere is an abnormal overgrowth of cells of the lymph system that is similar in many ways to lymphomas[1] (cancers of lymph nodes).

Even though CD is not officially a cancer, one form of this disease (known as

multicentric Castleman disease) acts very much like lymphoma. In fact, many people with this disease eventually develop lymphomas. And like lymphoma, CD is often treated with chemotherapy[2] or radiation therapy[3]. This is why it is included in the American Cancer Society's cancer information. (For information about lymphoma, see Hodgkin Disease[4] and Non-Hodgkin Lymphoma[5].).

About lymph nodes and lymphoid tissue

To understand Castleman disease, it helps to know about the body's lymph system.

Lymphoid tissue, also known as lymphatic tissue, is the main part of the immune system. It is formed by different types of cells that work together to help the body fight infections. The main cells in lymphoid tissue are lymphocytes, a type of white blood cell. There are 2 main types of lymphocytes: B cells and T cells.

Lymphoid tissue is found in many places throughout the body, including:

- **Lymph nodes:** bean-sized collections of lymphocytes found in small groups throughout the body, including inside the chest, abdomen, and pelvis. They can sometimes be felt under the skin in the neck, under the arms, and in the groin.
- **Thymus:** a small organ behind the upper part of the breastbone and in front of the heart. The thymus plays a vital role in development of T cells.
- **Spleen:** an organ under the lower part of the rib cage on the left side of the body. The spleen makes lymphocytes and other immune system cells to help fight infection. It also stores healthy blood cells and helps filter the blood.
- **Tonsils and adenoids:** collections of lymphoid tissue at the back of the throat. They help protect the body against germs that are breathed in or swallowed.
- **Bone marrow:** the soft inner part of certain bones that makes red blood cells, blood platelets, and white blood cells (including lymphocytes).
- **Digestive tract:** the stomach, intestines, and other organs, which also have lymphoid tissue.

Types of Castleman disease

Doctors can group CD in a number of ways, and they are still trying to determine which classification (or combination of them) provides the most helpful information.

CD is classified by on how much of the body it affects. The main forms of CD are called

localized and **multicentric**. They affect people very differently.

Localized (unicentric) Castleman disease

This is the more common type of CD. Localized CD only affects a single group of lymph nodes. It is not widespread. Lymph nodes in the chest or abdomen are affected most often. CD causes these lymph nodes to grow.

Enlarged lymph nodes in the chest can press on the windpipe (trachea) or smaller breathing tubes going into the lungs (bronchi), causing breathing problems. If the enlarged nodes are in the abdomen, the person might have pain, a feeling of fullness, or trouble eating. Sometimes the enlarged nodes are in places such as the neck, groin, or underarm area and are first noticed as a lump under the skin.

People with localized CD are usually cured when the affected lymph nodes are removed with surgery[6].

Multicentric Castleman disease

Multicentric Castleman disease (MCD) affects more than one group of lymph nodes. It can also affect other organs containing lymphoid tissue. This form sometimes occurs in people infected with human immunodeficiency virus (HIV), the virus that causes AIDS. Multicentric CD is more serious than the localized type, particularly in people with HIV infection. You can read more about HIV infection in HIV, AIDS, and Cancer[7].

People with MCD often have problems such as serious infections, fevers, weight loss, fatigue, night sweats, and nerve damage that can cause weakness and numbness. Blood tests often show too few red blood cells (anemia) and high levels of antibodies in the blood (hypergammaglobulinemia).

MCD can weaken the body's immune system, making it hard to fight infection. Infections in people with MCD can be very serious, even life threatening. MCD also increases the risk of developing lymphoma[8], a cancer of lymphoid tissue, which can often be hard to treat.

Microscopic subtypes of CD

Castleman disease can also be classified based on how the lymph node tissue looks under a microscope. These are called **microscopic subtypes**.

- The **hyaline vascular** type is most common. It tends to be localized, in which case

people often have few symptoms and usually have a good outlook, but in rare cases it can be multicentric.
- The **plasma cell** type is more likely to cause symptoms and to be multicentric, but it is sometimes localized.
- The **mixed** subtype shows areas of both hyaline vascular and plasma cell types. It occurs less often.
- The **plasmablastic** type was recognized more recently. Like the plasma cell type, it is usually multicentric, usually causes symptoms, and has a less favorable outlook.

In choosing treatments[9], doctors believe that the microscopic type is less important than whether the disease is localized or multicentric.

Subtypes of CD based on viral infections

Infection with certain viruses plays a role in at least some cases of CD.

Multicentric CD is more common in people infected with HIV[10], the virus that causes AIDS. Doctors sometimes group patients with multicentric CD into those who are infected with HIV (HIV positive) and those who are not infected (HIV negative).

In recent years, it's become clear that another virus, known as human herpesvirus-8 (HHV-8) or Kaposi sarcoma herpesvirus (KSHV), is often found in the lymph node cells of people with multicentric CD. In fact, HHV-8 is found in the lymph nodes of nearly all CD patients who are HIV positive. Some doctors have suggested classifying CD based on whether the cells contain HHV-8.

Hyperlinks

1. www.cancer.org/cancer/lymphoma.html
2. www.cancer.org/cancer/castleman-disease/treating/chemotherapy.html
3. www.cancer.org/cancer/castleman-disease/treating/radiation.html
4. www.cancer.org/cancer/hodgkin-lymphoma.html
5. www.cancer.org/cancer/non-hodgkin-lymphoma.html
6. www.cancer.org/cancer/castleman-disease/treating/surgery.html
7. www.cancer.org/cancer/cancer-causes/infectious-agents/hiv-infection-aids.html
8. www.cancer.org/cancer/lymphoma.html
9. www.cancer.org/cancer/castleman-disease/treating.html
10. www.cancer.org/cancer/cancer-causes/infectious-agents/hiv-infection-aids.html

References
Castleman Disease Collaborative Network. *About Castleman disease*. http://www.cdcn.org/about-castleman-disease/. Accessed January 5, 2018.

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: *Hematology: Basic Principles and Practice*, 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Verc ellino L, Meignin V, Gerard L, Galicier L. The full spectrum of Castleman disease: 273 patients studied over 20years. *Hematol Oncol Clin North Am*.2018;32(1):75-88.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Wong RSM. Unicentric Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):65-73.

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies. In: *DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 1, 2018

Key Statistics for Castleman Disease

We aren't sure how many people are diagnosed with Castleman disease (CD) each year. The National Cancer Institute keeps track of how many people have each type of cancer, but because CD is not a cancer it is not included. We do know that CD is rare,

especially in people who are otherwise healthy. Recent studies that looked at medical records of patients with CD suggest there may be about 4,300 to 5,100 new cases of CD per year in the US.

- The localized (unicentric) form of CD is more common than the multicentric form (MCD).
- MCD is much more likely to occur in people infected with HIV. Over the past few decades, as the number of people with HIV infection has increased, the number of people diagnosed with MCD has also gone up.
- Modern anti-viral treatments have helped people with HIV live much longer, but these drugs don't seem to lower the chance of getting MCD.
- CD can affect children as well as adults. Younger people are more likely to have the localized form.
- Older adults and those with HIV infection are more likely to have the multicentric form.

For statistics related to survival, see Survival Rates for Castleman Disease[1].

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/detection-diagnosis-staging/outlook.html

References

Castleman Disease Collaborative Network. *About Castleman disease*. http://www.cdcn.org/about-castleman-disease/. Accessed January 5, 2018.

Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. *Leuk Lymphoma*. 2015;56(5):1252-1260.

National Cancer Institute. *Castleman disease*. Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gerard L, Galicier L. The full spectrum of Castleman disease: 273 patients studied over 20years. *Hematol Oncol Clin North Am*.2018;32(1):75-88.

Simpson D. Epidemiology of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):1-10.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 1, 2018

What's New in Castleman Disease Research?

Important research on Castleman disease (CD) is going on in many university hospitals, medical centers, and other institutions around the world. Scientists are learning more about what causes the disease and how best to treat it. Unfortunately, research into this disease is slowed by the fact that CD is rare.

Causes

Doctors have learned a great deal about some of the possible causes of CD in recent years. For example, many people with multicentric CD (MCD) have been found to have evidence of infection with a virus known as human herpesvirus-8 (HHV-8) in their lymph nodes. Genetic mutations that happen throughout life, and inflammation, are also possible causes of certain kinds of CD. Knowing this type of information might help researchers come up with new ways of treating this disease. But there’s a lot we still don’t know about the exact causes of CD.

Treatment

Researchers have begun to study several promising new drugs for use against CD in recent years.

Many patients with MCD have too much of a protein called interleukin-6 (IL-6) in their blood. Drugs that target IL-6 have shown promise against MCD. One of these drugs, siltuximab, is a monoclonal antibody that binds to IL-6, which stops it from reaching lymphocytes. This drug is now approved for use in people with MCD who are not infected with HIV or HHV-8 (see Immunotherapy for Castleman Disease[1]).

Another monoclonal antibody, tocilizumab (Actemra®), blocks the action of IL-6 by binding to its receptor on lymphocytes. This drug is being studied for use against MCD. It is already approved to treat rheumatoid arthritis in the United States, and some doctors use it to treat MCD as well.

It is unclear how helpful these drugs will be in MCD patients who are HIV-positive, since few HIV-positive patients have been in the studies so far. Still, these drugs offer hope for the future treatment of MCD.

Other drugs being studied for treatment of CD include:

- Sirolimus, cyclosporine, and mycofenolate mofetil: These drugs suppress the immune system, so they are often used in autoimmune diseases or to help prevent the rejection of organ transplants, but they may also be helpful in CD.
- Suramin: This drug is thought to work by stopping IL-6 from attaching to and affecting lymphocytes.
- Bortezomib (Velcade): This drug is used mainly to treat multiple myeloma, but some reports also suggest it might help some people with CD.
- Rituximab (Rituxan): This drug is used to treat certain kinds of lymphoma and may be helpful in CD.
- Silmitasertib or CX-4945: This oral drug blocks CK2, a protein that helps some cells grow and divide. It is still in the earliest phases of testing for CD.

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/treating/immunotherapy.html

References

National Cancer Institute. *Castleman disease*. Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017*. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 1, 2018

Written by

The American Cancer Society medical and editorial content team (www.cancer.org/cancer/acs-medical-content-and-news-staff.html)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Causes, Risk Factors, and Prevention of Castleman Disease

Risk Factors for Castleman Disease

A risk factor is anything that affects your chance of getting a disease.

- Castleman Disease Risk Factors

Causes of Castleman Disease

Researchers continue to investigate the causes of Castleman disease. Learn more about what is known.

- What Causes Castleman Disease?

Castleman Disease Risk Factors

A risk factor is anything that might change a person's chance of getting a disease. Some risk factors, like smoking, can be changed. Others, like a person's age or family history, can't be changed. But having a risk factor, or even several, doesn't mean that a person will get the disease. And, many people who get the disease may have few or no known risk factors.

Most patients with Castleman disease (CD) don't have any known risk factors.

The only clear risk factor for CD is infection with HIV, the virus that causes AIDS[1]. The multicentric form of Castleman disease is much more common in people with HIV infection, particularly in those who have developed AIDS. This might be because these people tend to have weakened immune systems, which allows the growth of another virus known as HHV-8 (see What Causes Castleman Disease?). It's not clear if people who have weakened immune systems for other reasons are also at higher risk.

Hyperlinks

1. www.cancer.org/cancer/cancer-causes/infectious-agents/hiv-infection-aids.html

References

Castleman Disease Collaborative Network. *About Castleman disease*. http://www.cdcn.org/about-castleman-disease/. Accessed January 5, 2018.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Simpson D. Epidemiology of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):1-10.

Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):37-52.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 1, 2018

What Causes Castleman Disease?

We do not know exactly what causes Castleman disease (CD). The main feature of CD is an overgrowth of lymphocytes (immune cells) called B cells. The cause of this overgrowth is not known for sure, but it seems to be related to problems with the way a

person's immune system is working. Many people with CD have abnormally high blood levels of certain substances made by immune system cells.

For example, in the multicentric form of CD (MCD), the body often makes too much of a protein called interleukin-6 (IL-6). IL-6 normally helps regulate immune function. Too much IL-6 can cause lymphocytes to grow and divide too quickly. But it's not clear what causes the high levels of IL-6.

One cause seems to be infection with human herpesvirus-8 (HHV-8), also known as Kaposi sarcoma herpesvirus (KSHV) (because it can cause Kaposi sarcoma[1]). HHV-8 is often found in the lymph node cells in people who have MCD, especially those who are HIV positive. HHV-8 can cause infected cells to make a form of IL-6, which could explain how it leads to CD.

Many people are infected with HHV-8, but in people with normal immune systems the virus doesn't seem to cause problems. People infected with HIV, however, often have weakened immune systems, which might allow HHV-8 to grow and cause problems. This could explain why people infected with HIV are more likely get MCD. Still, some people with HIV who develop MCD do not have weakened immune systems, so it's not clear if this is the only reason.

HHV-8 hasn't been found in all cases of MCD. And it's not clear what causes the localized (unicentric) form of CD. Researchers are still looking for the causes of CD in these other cases.

Hyperlinks

1. www.cancer.org/cancer/kaposi-sarcoma.html

References

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Simpson D. Epidemiology of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):1-10.

Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):37-52.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 8, 2018

Written by

The American Cancer Society medical and editorial content team (www.cancer.org/cancer/acs-medical-content-and-news-staff.html)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

cancer.org | 1.800.227.2345

Early Detection, Diagnosis, and Staging of Castleman Disease

Detection and Diagnosis

Some people with Castleman disease may have signs and symptoms that can be noticed, but that is not always the case.

- Signs and Symptoms of Castleman Disease
- Tests for Castleman Disease

Staging and Outlook (Prognosis)

Learn how staging provides information about the extent of disease and anticipated response to treatment.

- Castleman Disease Stages
- Survival Rates for Castleman Disease

Questions To Ask About Castleman Disease

Here are some questions you can ask to help you better understand your diagnosis and treatment options.

- Questions to Ask About Castleman Disease

Signs and Symptoms of Castleman Disease

Castleman disease (CD) can cause a lot of different types of symptoms, and in some people it might not cause any symptoms at all. If symptoms do occur, they are often like those seen with other diseases, such as infections, autoimmune diseases, or even some types of cancer. Because of this, doctors might not suspect CD at first.

Common symptoms of localized CD

In the localized form of CD, symptoms are found in a particular part of the body. Localized CD often starts as an enlarged lymph node. If the node is just under the skin, such as in the neck or underarm area, it might be seen or felt as a lump. But if it's in the chest or abdomen (belly), it might not be noticed until it grows large enough to cause other symptoms:

- An enlarged node in the chest might press on the windpipe, which could cause trouble breathing, wheezing, a cough, or a feeling of fullness in the chest.
- An enlarged node in the abdomen can cause trouble eating, pain, or just a feeling of fullness.

In general, most people with localized CD feel well otherwise. In fact, some people have no symptoms at all, and CD is found only when the doctor does a test for another reason. On the other hand, some people with localized CD can also have some of the other symptoms listed below.

Common symptoms of multicentric CD

People with multicentric CD have more than one area of enlarged lymph nodes. The enlarged nodes can be in the chest or abdomen, but multicentric CD often affects lymph nodes in the groin, the underarm area, and on the sides of the neck, which can often be seen or felt as lumps under the skin.

Multicentric CD can also affect lymphoid tissue of internal organs, causing the liver, spleen, or other organs to enlarge. Enlarged organs might be seen or felt as masses under either side of the rib cage. They can also cause problems eating or a sense of fullness (or even pain) in the abdomen.

Other symptoms of CD

In addition, people with either type of CD can have other symptoms (although these symptoms are much more common in people with multicentric CD):

- Fever
- Night sweats (that soak the sheets)
- Weight loss
- Loss of appetite
- Weakness
- Fatigue (tiredness)
- Shortness of breath
- Nausea and vomiting
- Nerve damage that leads to numbness and weakness (neuropathy)
- Leg swelling (edema)
- Skin rashes

Some of these symptoms might come and go over time.

Amyloidosis, a condition where abnormal proteins build up in body tissues, can occur in CD. This can lead to kidney damage, heart damage, nerve damage, and intestinal problems, mainly diarrhea. If CD is treated successfully, the amyloidosis may improve or even go away.

Anemia(having too few red blood cells) is very common in multicentric CD, and can lead to problems such as fatigue and shortness of breath.

CD is rare, and the symptoms above often have other causes. Still, if you have any of these symptoms and they don't go away within a few weeks (or they get worse), see a doctor so that the cause can be found and treated, if needed.

References

Castleman Disease Collaborative Network. *About Castleman disease.* http://www.cdcn.org/about-castleman-disease/. Accessed January 5, 2018.

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed.

Philadelphia, PA. Elsevier; 2014:1991-2017.

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: *Hematology: Basic Principles and Practice.* 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Szalat R, Munshi NC. Diagnosis of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):53-64.

Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):37-52.

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

Mauermann ML. The peripheral neuropathies of POEMS syndrome and Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):153-163.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 10, 2017 Last Revised: February 7, 2018

Tests for Castleman Disease

People with Castleman disease (CD) may see their doctor because of symptoms they are having, or because they just don't feel well and go in for a checkup. Sometimes CD is found in people without symptoms when it's found on an imaging or blood test[1] being

done for another reason.

CD is rare, and its symptoms are often like those caused by other diseases (including infections, autoimmune diseases, and lymphomas[2]), so doctors often suspect it is something else at first. The diagnosis of CD does involve looking at any symptoms the patient may have and blood test results. However, an actual diagnosis is made when doctors remove an affected lymph node and look at it with a microscope. This procedure, known as a **biopsy**, is described below.

Medical history and physical exam

If your symptoms or the results of a test suggest you might have a lymph node problem such as CD, your doctor will want to get a thorough medical history, including the details of any symptoms, possible risk factors[3], family history, and other medical conditions.

Next, the doctor will examine you, paying special attention to lymph nodes and other areas of your body that could be involved, including the spleen and liver. Because infections are the most common cause of enlarged lymph nodes, the doctor will look for an infection in the part of the body near the swollen lymph nodes.

If the doctor suspects that CD or another serious problem (such as lymphoma) might be causing the symptoms, he or she will probably order blood tests, imaging tests, and/or do a biopsy of an affected lymph node (see below).

Blood tests

Blood tests are likely to be done if the doctor suspects CD, some other type of immune system problem, a serious infection, or other conditions. Some of the types of blood tests that can be abnormal in people with CD include:

- Complete blood count (CBC)
- Interleukin-6 (IL-6)
- Erythrocyte sedimentation rate (ESR)
- C-reactive protein (CRP)
- Kidney function tests

Having abnormal results for these lab tests doesn’t prove someone has CD, because other conditions can also cause these problems. But these and other blood tests can help doctors make the right diagnosis.

Imaging tests

Imaging tests use x-rays, magnetic fields, sound waves, or radioactive particles to create pictures of the inside of the body. These tests may be done for a number of reasons, including

- To look for enlarged lymph nodes or organs that might be causing symptoms
- To look for enlarged nodes in other parts of the body
- To help determine if treatment[4] is working

People who might have CD (or another lymph node problem) may have one or more of the following tests.

Computed tomography (CT) scan

The CT scan[5] uses x-rays to make detailed cross-sectional images of your body. Unlike a regular x-ray, CT scans can show the detail in soft tissues (such as internal organs). This scan can help tell if any lymph nodes or organs in your body are larger than normal.

CT-guided needle biopsy: In some cases, CT scans can also be used to guide a biopsy needle precisely into a lymph node. A small sample of the node is then removed and looked at with a microscope. A needle biopsy can't diagnose CD by itself, but it can sometimes help diagnose or exclude other diseases that can cause large lymph nodes.

Magnetic resonance imaging (MRI)

MRI[6] is not used as often as CT scans for lymph node problems, but if your doctor is concerned about areas near your spinal cord or brain, MRI is very useful for looking at these areas.

Like CT scans, MRI scans show detailed images of soft tissues in the body. But MRI scans use radio waves and strong magnets instead of x-rays.

Chest x-ray

This test might be done if you're having breathing problems, to find out if there are enlarged lymph nodes in your chest (usually in the center part of the chest between the lungs, the **mediastinum).**.

Ultrasound

Ultrasound[7] uses sound waves and their echoes to create pictures of internal organs or masses.

Ultrasound can be used to look at lymph nodes near the surface of your body or to look inside your abdomen for enlarged lymph nodes or organs such as the liver and spleen. It can also show kidneys that have become swollen because the outflow of urine has been blocked by enlarged lymph nodes. (It can't be used to look at organs or lymph nodes in the chest because the ribs block the sound waves.)

Positron emission tomography (PET) scan

PET scans[8] are helpful in finding small collections of fast-growing cells that might not be visible on a CT scan. PET is not often used to diagnose CD, but sometimes it can help the doctor determine the cause of enlarged lymph nodes.

For a PET scan, you are injected with a slightly radioactive form of sugar, which collects mainly in cancer cells. A special camera is then used to create a picture of areas of radioactivity in the body. The picture is not detailed like a CT or MRI scan, but a PET scan can look for possible areas of cancer spread in all areas of the body at once.

Some newer machines can do both a PET and CT scan at the same time (PET/CT scan). This lets the doctor see areas that "light up" on the PET scan in more detail.

Gallium scan

For this test, you are injected with a solution containing slightly radioactive gallium. It is attracted to lymph tissue in the body. A few days later a special camera is used to detect the radioactivity, showing the location of the gallium. A gallium scan can sometimes find unsuspected sites of CD disease, but it is not always reliable since the gallium might not be taken up by all of the lymph nodes affected by CD.

This test is not used as much now as in the past, as many doctors do a PET scan instead.

Lymph node biopsy

A doctor might suspect you have Castleman disease based on your symptoms or the results of exams or tests, but it can only be diagnosed by removing an enlarged lymph node and examining it under the microscope. This procedure is called a **biopsy**.

Different types of biopsies can be used, based on where the lymph node is.

Excisional or incisional biopsy: If the lymph node is near the skin surface, a surgeon can often remove the node using local anesthesia (numbing medicine). The surgeon cuts the skin over the enlarged lymph node, removes the node, and then stitches the cut closed.

- If the procedure removes the entire lymph node, it is called an excisional biopsy.
- If only part of the node is removed, it is called an incisionalbiopsy.

If the lymph node is in the chest or the abdomen, the surgeon might need to make a large incision to get into either of these places. This type of surgery might require general anesthesia (where you are in a deep sleep), but it might be needed to learn why the lymph node is enlarged.

Sometimes, lymph nodes in the chest can be removed by **mediastinoscopy**. In this procedure, a small cut is made in the front of the neck and a thin, hollow, lighted tube (called a mediastinoscope) is inserted behind the sternum (breast bone) and in front of the windpipe to look at the area. Special instruments can be passed through this tube to remove all or part of a lymph node.

The same type of procedure can be used to sample lymph nodes in the abdomen. In this case, the test is known as **laparoscopy**. The doctor makes a small cut in the abdomen and inserts a thin, hollow, lighted tube (called a laparoscope) and other instruments to look at the area and remove all or part of a lymph node.

Fine needle aspiration (FNA) or core needle biopsy: Sometimes lymph nodes are biopsied by putting a hollow needle into the node to remove a small amount of tissue. In a fine needle aspiration (FNA) biopsy, the doctor uses a very thin needle to withdraw (aspirate) a small amount of tissue from the enlarged node. For a core needle biopsy, the doctor uses a larger needle to remove a slightly larger piece of tissue.

Doctors have found that diagnosing CD by needle biopsy is sometimes possible, but biopsy methods that remove larger samples of tissue are usually recommended because they are thought to be more accurate.

Lab tests of biopsy samples

No matter what procedure is used to take a biopsy, the cells from the biopsy are then sent to a lab. Using a microscope, a doctor called a pathologist looks at them and might do other tests[9]. Since CD is so rare, the pathologist might ask another pathologist with

special training in diagnosing blood and lymph node diseases (called a hematopathologist) to look at the biopsy.

Sometimes it's hard to tell if the lymph node is affected by CD or by lymphoma. In these cases, other tests might be done on the lymph node tissue to help figure this out. Some tests look at the proteins on the surface of the cells, while others look for gene or chromosome changes within the cells. Examples of these lab tests include:

- Immunohistochemistry
- Flow cytometry
- Cytogenetics
- Fluorescent in situ hybridization (FISH)
- Polymerase chain reaction (PCR)

These tests, are described in more detail in Non-Hodgkin Lymphoma[10].

Hyperlinks

1. www.cancer.org/treatment/understanding-your-diagnosis/tests.html
2. www.cancer.org/cancer/lymphoma.html
3. www.cancer.org/cancer/castleman-disease/causes-risks-prevention/risk-factors.html
4. www.cancer.org/cancer/castleman-disease/treating.html
5. www.cancer.org/treatment/understanding-your-diagnosis/tests/ct-scan-for-cancer.html
6. www.cancer.org/treatment/understanding-your-diagnosis/tests/mri-for-cancer.html
7. www.cancer.org/treatment/understanding-your-diagnosis/tests/ultrasound-for-cancer.html
8. www.cancer.org/treatment/understanding-your-diagnosis/tests/nuclear-medicine-scans-for-cancer.html
9. https://author-prod.cancer.org/content/cancer/en/treatment/understanding-your-diagnosis/tests/testing-biopsy-and-cytology-specimens-for-cancer.html
10. www.cancer.org/cancer/non-hodgkin-lymphoma.html

References

Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis,

and therapy. *Blood*. 2014;123(19):2924-2933.

Fajgenbaum DC, Shilling D.
Castleman disease pathogenesis. *Hematol Oncol Clin North Am*.2018;32(1):11-21.

Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/ idiopathic multicentric Castleman disease. *Blood*. 2017;129(12):1646-1657.

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Liebman HA, Tulpule A. Hematologic manifestations of HIV/AIDS.
In: *Hematology: Basic Principles and Practice.* 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 2262-2277.

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: A systematic literature review. *Lancet Haematol.* 2016;3(4):e163-165.

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: *Hematology: Basic Principles and Practice.* 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders
In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology.* 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Szalat R, Munshi NC. Diagnosis of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):53-64.

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies.
In: *DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

Yoshizaki K, Murayama S, Ito H, Koga T. The role of interleukin-6 in Castleman

disease. *Hematol Oncol Clin North Am*.2018;32(1):23-36.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 10, 2017 Last Revised: February 2, 2018

Castleman Disease Stages

After someone is diagnosed with cancer, doctors will try to figure out if it has spread and if so, how far. This process is called **staging**. The stage of a cancer describes how much cancer is in the body. It helps determine how serious the cancer is and how best to treat[1] it. Doctors also use a cancer's stage when talking about survival statistics.

Since Castleman disease (CD) is not a cancer, it doesn't have a formal staging system. Instead, doctors use other important pieces of information to help decide on the best treatment and to give them an idea of how well a patient might do.

The most important factor when deciding on treatment is whether the CD is localized/unicentric or multicentric.[2] Localized/unicentric CD affects only a single lymph node (or lymph node group). The multicentric type affects 2 or more groups of lymph nodes in different parts of the body. It may also affect organs like the spleen or liver. Tests are done to see what lymph nodes and organs are affected to learn which type of CD a patient has. Doctors use the results of physical exams and imaging, such as a chest x-ray and either a CT scan or MRI of the chest and abdomen. These are described in Tests for Castleman Disease.

Another factor is the microscopic subtype of the CD, which is a description of the patterns of cells seen under the microscope in the biopsy sample. These subtypes are described in What Is Castleman Disease?[3]

A third important factor is whether or not the patient is infected with the human immunodeficiency virus (HIV), the virus that causes AIDS. Just about all people infected with HIV who develop CD will have the multicentric form of the disease.

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/treating.html
2. www.cancer.org/cancer/castleman-disease/about/what-is-castleman-disease.html
3. www.cancer.org/cancer/castleman-disease/about/what-is-castleman-disease.html

References

Fajgenbaum DC, Shilling D.
Castleman disease pathogenesis. *Hematol Oncol Clin North Am*.2018;32(1):11-21.

Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative,
idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy. *Blood*. 2014;123(19):2924-2933.

Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8- negative/ idiopathic multicentric Castleman disease. *Blood*. 2017;129(12):1646-1657.

Liebman HA, Tulpule A. Hematologic manifestations of HIV/AIDS.
In: *Hematology: Basic Principles and Practice.* 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 2262-2277.

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al.
Idiopathic multicentric Castleman's disease: A systematic literature review. *Lancet Haematol.* 2016;3(4):e163-165.

Szalat R, Munshi NC. Diagnosis of Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):53-64.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 10, 2017 Last Revised: February 2, 2018

Survival Rates for Castleman Disease

Doctors often use survival rates as a standard way of discussing a person's outlook (prognosis). Survival rates tell you what portion of people with the same type and stage of disease are still alive a certain amount of time after they were diagnosed. They can't tell you how long you will live, but they may help give you a better understanding about how likely it is that your treatment will be successful.

It's hard to get accurate numbers on the outlook for people with CD because it is rare. Most statistics on the disease come from small numbers of patients who were treated at a single center or hospital. These numbers might not accurately reflect the outcomes for all people with CD.

The numbers below come from a study of nearly 200 people treated for CD in many different centers. The study divided people into groups[1] based on whether the CD was unicentric or multicentric, its microscopic subtype, and whether the patient was infected with HIV (HIV+) or not infected (HIV-).

The 3-year **disease-free survival (DFS)** rate refers to the percentage of patients who were still alive and had no signs of CD at least 3 years after it was diagnosed. Of course, many people went much longer than 3 years without any signs of CD (and many were likely cured).

Type of Castleman Disease	3-Year Disease-Free S
Unicentric, hyaline vascular, HIV-	93%
Unicentric, plasma cell or mixed, HIV-, OR Multicentric, hyaline vascular, HIV-	79%
Multicentric, plasma cell, HIV-	46%
HIV+ (multicentric)	28%

Even when taking the factors above into account, disease-free survival rates are at best rough estimates. If you have CD, your doctor can tell you how well these numbers might apply to you, as he or she knows your situation best.

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/about/what-is-castleman-disease.html

References

Castleman Disease Collaborative Network. *About Castleman disease*. http://www.cdcn.org/about-castleman-disease/. Accessed January 5, 2018.

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: A systematic literature review. *Lancet Haematol* 2016;3(4):e163-165.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gerard L, Galicier L. The full spectrum of Castleman disease: 273 patients studied over 20years. *Hematol Oncol Clin North Am*.2018;32(1):75-88.

Talat N, Schulte KM. Castleman's disease: Systematic analysis of 416 patients from the literature. *Oncologist*. 2011;16:1316–1324.

Zhang X, Rao H, Xu X, Li Z, Liao B, Wu H, Li M, Tong X, Li J, Cai Q. Clinical characteristics and outcomes of Castleman disease: Amulticenter study of 185 Chinese patients. *Cancer Sci*. 2017 Nov [Epub ahead of print].

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 10, 2017 Last Revised: February 8, 2018

Questions to Ask About Castleman Disease

It's important to have honest, open discussions with your cancer care team. Ask any question, no matter how small it might seem. Some questions to consider:

When you're told you have Castleman disease (CD)

- Is my CD localized or multicentric[1]?
- Has my biopsy been reviewed by a pathologist who is an expert on CD?

- Do I also have HIV infection and AIDS[2]? If so, how does it influence my prognosis (outlook) and treatment of CD?
- Do I need other tests before we can decide on treatment?
- Are there other doctors I need to see?

When deciding on a treatment plan

- How much experience do you have treating CD?
- Should I get a second opinion before starting treatment? Can you suggest a doctor or treatment center?
- What treatment choices[3] do I have? Do we need to start treatment right away?
- Am I eligible for clinical trials[4] of any new treatments?
- Which treatment do you recommend, and why?
- What are the side effects of the treatments that you recommend?
- What can I do to help reduce the side effects I may have from the treatment?
- What should I do to be ready for treatment?
- How long will treatment last? What will it be like? Where will it be done?
- How will treatment affect my daily activities?
- What is my outlook for survival?
- What are the chances of the CD coming back with these treatment plans?

During treatment

- What would we do if the treatment doesn't work or if the CD comes back?
- What type of follow-up[5] will I need after treatment?
- What symptoms or side effects should I tell you about right away?
- How can I reach you on nights, holidays, or weekends?
- Do I need to change what I eat during treatment?
- Are there any limits on what I can do?
- Should I exercise? What should I do, and how often?
- Can you suggest a mental health professional I can see if I start to feel overwhelmed, depressed, or distressed?

After treatment

- Are there any limits on what I can do?
- What symptoms should I watch for?
- What kind of exercise should I do now?
- What type of follow-up will I need after treatment?
- How often will I need to have follow-up exams and tests?
- How will we know if the cancer has come back? What should I watch for?
- What will my options be if the cancer comes back?

Along with these sample questions, be sure to write down some of your own. For instance, you might want more information about recovery times so that you can plan your work or activity schedule.

Keep in mind that doctors aren't the only ones who can give you information. Other health care professionals, such as nurses and social workers, can answer some of your questions. For more about speaking with your health care team, see Talking With Your Doctor[6].

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/about/what-is-castleman-disease.html
2. www.cancer.org/cancer/cancer-causes/infectious-agents/hiv-infection-aids.html
3. www.cancer.org/cancer/castleman-disease/treating.html
4. www.cancer.org/treatment/treatments-and-side-effects/clinical-trials.html
5. www.cancer.org/cancer/castleman-disease/after-treatment.html
6. /ssLINK/talking-with-your-doctor-toc

References

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 10, 2017 Last Revised: February 8, 2018

Written by

The American Cancer Society medical and editorial content team (www.cancer.org/cancer/acs-medical-content-and-news-staff.html)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

cancer.org | 1.800.227.2345

Treating Castleman Disease

How is Castleman disease treated?

Several types of treatment can be used to treat Castleman disease, including:

- Surgery for Castleman Disease
- Radiation Therapy for Castleman Disease
- Corticosteroids for Castleman Disease
- Chemotherapy for Castleman Disease
- Immunotherapy for Castleman Disease
- Anti-viral Drugs for Castleman Disease

Common treatment approaches

Your treatment options will be based on whether the CD is localized (unicentric) or multicentric, as well as other factors when these are important. Because CD is rare, it has been hard to do studies to learn the best ways to treat it. Of course, no two patients are exactly alike, so treatment is tailored to each person's situation.

- Treatment of Localized (Unicentric) Castleman Disease
- Treatment of Multicentric Castleman Disease

Who treats Castleman disease?

Based on your treatment options, you might have different types of doctors on your treatment team, including:

- A **surgeon**
- A **hematologist:** a doctor who treats disorders of the blood and lymph system,

including CD
- A **medical oncologist:** a doctor who treats cancer and similar diseases with medicines
- A **radiation oncologist:** a doctor who treats cancer and similar diseases with radiation therapy

You might have other specialists on your treatment team as well, including physician assistants (PAs), nurse practitioners (NPs), nurses, psychologists, nutrition specialists, social workers, rehabilitation specialists, and other health professionals.

- Health Professionals Associated With Cancer Care[1]

Making treatment decisions

It's important to discuss all of your treatment options, including the goals of treatment and possible side effects, with your doctors to help make the decision that best fits your needs. In choosing a treatment plan, consider your health and the type of CD. Be sure that you understand all the risks and side effects of the various treatments before making a decision. Ask your health care team questions.

CD is a rare disease, so not many doctors have much experience treating it. If time allows, it's often a good idea to seek a second opinion. Getting a second opinion can give you more information and help you feel confident about the treatment plan that you choose. Your doctor should be willing to help you find another doctor who can give you a second opinion.

- Questions to Ask About Castleman Disease[2]
- Seeking a Second Opinion[3]

Thinking about taking part in a clinical trial

Clinical trials are carefully controlled research studies that are done to get a closer look at promising new treatments or procedures. Clinical trials are one way to get state-of-the art cancer treatment. In some cases they may be the only way to get access to newer treatments. They are also the best way for doctors to learn better methods to treat illnesses such as Castleman disease. Still, they're not right for everyone.

If you would like to learn more about clinical trials that might be right for you, start by asking your doctor if your clinic or hospital conducts clinical trials.

- Clinical Trials[4]

Considering complementary and alternative methods

You may hear about alternative or complementary methods that your doctor hasn't mentioned to treat your cancer or relieve symptoms. These methods can include vitamins, herbs, and special diets, or other methods such as acupuncture or massage, to name a few.

Complementary methods refer to treatments that are used along with your regular medical care. Alternative treatments are used instead of a doctor's medical treatment. Although some of these methods might be helpful in relieving symptoms or helping you feel better, many have not been proven to work. Some might even be harmful.

Be sure to talk to your care team about any method you are thinking about using. They can help you learn what is known (or not known) about the method, which can help you make an informed decision.

- Complementary and Alternative Medicine[5]

Help getting through treatment

Your care team will be your first source of information and support, but there are other resources for help when you need it. Hospital- or clinic-based support services are an important part of your care. These might include nursing or social work services, financial aid, nutritional advice, rehab, or spiritual help.

The American Cancer Society also has programs and services – including rides to treatment, lodging, and more – to help you get through treatment. Call our National Cancer Information Center at 1-800-227-2345 and speak with one of our trained specialists.

- Find Support Programs and Services in Your Area[6]

Choosing to stop treatment or choosing no treatment at all

Because CD is not a cancer but may lead to cancer, it's important to talk through your decision with your doctors. For some people, when treatments may not be helpful or are no longer working, it may be time to weigh the benefits and risks of continuing to try new treatments. Whether or not you continue treatment, there are still things you can do to

help maintain or improve your quality of life.

- Palliative or Supportive Care[7]

The treatment information given here is not official policy of the American Cancer Society and is not intended as medical advice to replace the expertise and judgment of your cancer care team. It is intended to help you and your family make informed decisions, together with your doctor. Your doctor may have reasons for suggesting a treatment plan different from these general treatment options. Don't hesitate to ask him or her questions about your treatment options.

Surgery for Castleman Disease

Surgery is often used to get a tissue sample to diagnose Castleman disease (CD). A lymph node biopsy (described in Tests for Castleman Disease[1]) is usually a minor procedure, and patients can often go home afterward.

Surgery also works well to treat localized (unicentric) CD. The type of surgery depends on where the disease is located.

If the affected lymph node or nodes are in a place that is easy to get to, such as in the armpit, then surgery is usually straightforward. In many cases the person may even be able to go home the same day after the surgery.

When the enlarged lymph nodes are in a place that is hard to get to, like deep in the chest or abdomen, surgery is more complex and might require a stay in the hospital for a few days after the operation.

Another option is to have radiation or treatment with chemotherapy or another drug first. This can shrink the lymph nodes or tumors, which can make them easier to remove with surgery.

Surgery might also be used to help treat symptoms rather than to try to cure the disease. For example, the spleen can be removed if it has grown large and is causing symptoms.

Potential side effects of surgery depend on several factors, including the extent of the

operation and a person's health before surgery. Most people will have at least some pain[2] after the operation, but it usually can be controlled with medicines if needed. Other problems can include reactions to anesthesia, damage to nearby organs during the operation, bleeding, blood clots in the legs, and skin infections at the incision sites.

Even though Castleman disease is not a cancer, surgery is often used in much the same way as it is for cancer. You can read more in Cancer Surgery[3].

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/detection-diagnosis-staging/diagnosis.html
2. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/pain.html
3. www.cancer.org/treatment/treatments-and-side-effects/treatment-types/surgery.html

References

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci*.2017;9 [Epub ahead of print].

National Cancer Institute. Physician Data Query (PDQ). *AIDS-related lymphoma treatment.* 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease*. Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017*. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018.

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Sarana B, Jaal J, Tamm H, Laisaar T. Resection of unicentric interlobar Castleman

disease with following adjuvant radiotherapy. *SAGE Open Med Case Rep*.2017;5:2050313X17744481.

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am.*2018;32(1):89-106.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 5, 2018

Radiation Therapy for Castleman Disease

Radiation therapy uses high-energy radiation to kill cells. It is sometimes used to treat localized Castleman disease (CD), especially if the affected lymph nodes can't be removed completely with surgery. Radiation can also be used as part of the treatment for multicentric CD.

Before your treatment starts, the radiation team will take careful measurements to find the correct angles for aiming the radiation beams and the proper dose of radiation. This planning session, called **simulation**, usually includes getting imaging tests[1] such as CT or MRI scans.

Radiation therapy is much like getting an x-ray, but the radiation is much stronger. The treatment itself is painless. It lasts only a few minutes, although the setup time – getting you into place for treatment – usually takes longer. You might get radiation treatment for several days in a row.

Possible side effects

Depending on where the radiation is aimed, side effects may include:

- Skin changes in areas getting radiation, ranging from redness to blistering and peeling

- Nausea and vomiting
- Diarrhea
- Fatigue
- Low blood counts

Most side effects[2] go away a short while after treatment ends, although fatigue and skin changes may last longer. Talk with your doctor about the possible side effects and the ways to reduce or relieve them.

Even though Castleman disease is not a cancer, radiation is often used in the same way as it is when people have cancer. To learn more, see Radiation Therapy[34].

Hyperlinks

1. /ssLINK/imaging-radiology-tests-for-cancer
2. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects.html
3. www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation.html
4. /content/cancer/en/treatment/treatments-and-side-effects/treatment-types/radiation/radiation-therapy-guide.html

References

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci*.2017;9 [Epub ahead of print].

National Cancer Institute. Physician Data Query (PDQ). *AIDS-related lymphoma treatment.* 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease*. Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017*. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018.

National Organization for Rare Disorders. *Castleman disease.* Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Sarana B, Jaal J, Tamm H, Laisaar T. Resection of unicentric interlobar Castleman disease with following adjuvant radiotherapy. *SAGE Open Med Case Rep*.2017;5:2050313X17744481.

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am.*2018;32(1):89-106.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 5, 2018

Corticosteroids for Castleman Disease

Corticosteroids are a group of drugs related to hormones made in the body by the adrenal glands. These drugs weaken the immune system, so they are useful in treating people with certain immune system diseases and cancers that develop from immune system cells, such as lymphomas[1].

In some patients with multicentric Castleman disease (CD), these drugs can be helpful, either alone or along with chemotherapy.

Corticosteroids are often taken as pills, but they can also be injected into a vein. Prednisone is the corticosteroid pill most often used to treat CD.

Side effects of corticosteroids (especially long-term use) can include increased blood sugar (which can lead to diabetes), mood changes, increased risk of infections[2], weakened bones, fatigue[3], muscle weakness, weight gain, fluid retention, and high blood pressure. Most of these side effects improve after the drug is stopped.

Hyperlinks

1. www.cancer.org/cancer/lymphoma.html
2. www.cancer.org/treatment/treatments-and-side-effects/physical-side-

effects/infections.html
3. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fatigue.html

References

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci.*2017;9 [Epub ahead of print].

National Cancer Institute. Physician Data Query (PDQ). *AIDS-related lymphoma treatment*. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease.* Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017.* Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. *Castleman disease*. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am.*2018;32(1):89-106.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 5, 2018

Chemotherapy for Castleman Disease

Chemotherapy (chemo) is the use of anti-cancer drugs that are injected into a vein or a muscle or are taken by mouth. These drugs enter the bloodstream and reach all areas of the body, making this treatment very useful for multicentric Castleman disease (CD). Chemo may be used alone, in combination with corticosteroids or other drugs, or combined with radiation therapy (called **chemoradiation**).

Many chemo drugs can be used to treat patients with multicentric CD. The drugs used most often include:

- Carmustine
- Cladribine
- Chlorambucil
- Cyclophosphamide
- Doxorubicin
- Etoposide
- Melphalan
- Vinblastine
- Vincristine

Often several drugs are combined. Because CD is similar to lymphomas[1] in many ways, doctors often use chemo combinations like those used for lymphoma. But because CD is so rare, there is not a lot of information on which chemo treatment is best or even how well it works.

Doctors give chemo in cycles, in which a period of treatment is followed by a rest period to give the body time to recover. Each chemo cycle generally lasts for several weeks. Most chemo treatments are given on an outpatient basis (in the doctor's office or clinic or hospital outpatient department) but some might require a hospital stay. Sometimes a patient takes one drug combination for several cycles and then later is switched to a different one.

Possible side effects

Chemo drugs attack cells that are dividing quickly, which is why they work against cancer and diseases like CD. But other cells in the body, such as those in the bone marrow (where new blood cells are made), the lining of the mouth and intestines, and the hair follicles, also divide quickly. These cells can also be affected by chemo, which can lead to certain side effects.

The side effects[2] of chemo depend on the type and dose of drugs given and the length

of time they are taken. These side effects can include:

- Hair loss
- Mouth sores
- Loss of appetite
- Nausea and vomiting[3]
- Diarrhea
- Increased risk of infections[4] (due to a shortage of white blood cells)
- Easy bruising and bleeding (due to a shortage of blood platelets)
- Fatigue[5] and weakness (due to a shortage of red blood cells)

Along with the risks above, some chemo drugs can cause other side effects. Ask your health care team about what side effects you can expect based on the specific drugs you will get. Be sure to tell your doctor or nurse if you do have side effects, as there are often ways to help with them. For example, drugs can be given to help prevent or reduce nausea and vomiting.

Even though Castleman disease is not a cancer, chemo is often used in much the same way as it is for cancer. To learn more, see Chemotherapy[6].

Hyperlinks

1. www.cancer.org/cancer/lymphoma.html
2. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects.html
3. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/nausea-and-vomiting.html
4. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/infections.html
5. www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fatigue.html
6. www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy.html

References

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci*.2017;9 [Epub ahead of print].

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease.* Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):89-106.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 20, 2017 Last Revised: February 5, 2018

Immunotherapy for Castleman Disease

Immunotherapy is treatment that either boosts the patient's own immune system or uses man-made versions of the normal parts of the immune system.

Monoclonal antibodies

Antibodies are proteins made by the body's immune system to help fight infections. Man-made versions, called **monoclonal antibodies**, can be designed to attack a specific target, such as a substance on the surface of lymphocytes, the cells in which Castleman disease (CD) starts. Sometimes they are given along with chemotherapy.

Siltuximab (Sylvant): This monoclonal antibody is used to treat some patients with multicentric CD. These patients often have high levels of a protein called IL-6. Siltuximab binds to IL-6, which keeps the protein from acting on lymphocytes. This drug doesn't seem to bind to IL-6 that is made from viruses, so it isn't meant for patients who are infected with either HIV or HHV-8. (IL-6, HIV, and HHV-8 were discussed in What Causes Castleman Disease?[1])

This drug is given as an infusion into a vein (IV), usually every 3 weeks.

Side effects tend to be mild and can include rash, itching, swelling, and weight gain. Some patients can also have side effects during the infusion, such as flushing (skin redness with a feeling of warmth), chest pain, back pain, nausea, and rapid heartbeat.

Rituximab (Rituxan): This monoclonal antibody is used widely for lymphoma[2]. It can also be helpful in treating CD. Rituximab attaches to a protein called CD20 that is found on the surface of some lymphocytes. This attachment causes the cell to die.

Side effects of rituximab are most common during the infusion, and can include chills, fever, nausea, rashes, fatigue, and headaches. Rarely, more severe side effects occur during the infusion, such as trouble breathing and low blood pressure. Unlike regular chemotherapy, rituximab does not cause low blood counts or hair loss.

This drug can also increase a person's risk of certain infections. In people who have ever been infected with the hepatitis B virus, this drug can sometimes cause the infection to become active again. Your doctor may check your blood for signs of a prior hepatitis infection before starting this drug to see if it is safe.

Tocilizumab (Actemra): This monoclonal antibody is used to treat some kinds of arthritis that can affect the immune system. Tocilizumab works by blocking certain messenger proteins, known as cytokines, that send signals between some cells of the immune system. Tocilizumab is sometimes used in unicentric and multicentric CD after other treatments have stopped working.

Side effects of tocilizumab include runny or stuffy nose, sinus pain, sore throat, headache, dizziness, itching, mild stomach cramps, or urinary tract infection (UTI). This drug also increases the risk for developing serious infections. Your doctor will monitor you closely during treatment.

Rituximab and tocilizumab are drugs that are given through infusion into a vein (IV) at the doctor's office or clinic.

Other antibodies: Newer antibodies that attack other targets are also being studied for

use against CD. These are discussed in What's New in Research of Castleman Disease?[3]

Immunomodulating drugs (IMiDs)

Drugs such as thalidomide (Thalomid) and lenalidomide (Revlimid) are used to treat certain cancers of immune cells such as multiple myeloma[4] and some types of lymphoma, but they have also helped some patients with CD.

These drugs are thought to work by affecting parts of a person's immune system. It's not exactly clear how they do this, but it seems to be at least in part by working against interleukin-6 (IL-6).

The drugs can cause side effects such as drowsiness, fatigue, constipation, low blood cell counts, and neuropathy (painful nerve damage). There is also an increased risk of serious blood clots (that start in the leg and can travel to the lungs). These tend to be more likely with thalidomide.

Because of concerns these drugs can cause severe birth defects if taken during pregnancy, they can only be obtained through special programs run by the drug company that makes them.

Interferon-alfa

Interferon-alfa is a hormone-like protein made by white blood cells in the body to help the immune system fight infections. Some patients with CD have improved with man-made interferon treatment.

Interferon is given by an injection, either daily or several times a week. This may be into a vein (IV), under the skin (SubQ), or into a muscle (IM). It may be given in a doctor's office, or you or a family member can be taught how to give the medicine under the skin.

Side effects of this treatment can include fatigue, fever, chills, headaches, muscle and joint aches, and mood changes. Because of its side effects, interferon is not used very often. It may be given to some patients in addition to chemotherapy.

Hyperlinks

1. www.cancer.org/cancer/castleman-disease/causes-risks-prevention/what-causes.html

2. www.cancer.org/cancer/lymphoma.html
3. www.cancer.org/cancer/castleman-disease/about/new-research.html
4. www.cancer.org/cancer/multiple-myeloma.html

References

Fajgenbaum DC, Kurzrock R. Siltuximab: A targeted therapy for idiopathic multicentric Castleman disease. *Immunotherapy.* 2016;8(1):17-26.

Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. *Clin Cancer Res*. 2013;19:3659–3670.

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci*.2017;9 [Epub ahead of print].

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease.* Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):89-106.

Yoshizaki K, Murayama S, Ito H, Koga T. The role of interleukin-6 in Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):23-36.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-

disease/references.html)

Last Medical Review: January 12, 2017 Last Revised: February 5, 2018

Anti-viral Drugs for Castleman Disease

Multicentric Castleman disease (CD) is sometimes associated with the virus HHV-8. Doctors have had success in treating some patients with multicentric CD with drugs that kill this virus, such as ganciclovir, valganciclovir, and foscarnet.

Many patients with HIV infection[1] are treated with anti-retroviral therapy to keep the HIV in check. But the effect of therapy for HIV on CD is not clear.

Hyperlinks

1. www.cancer.org/cancer/cancer-causes/infectious-agents/hiv-infection-aids.html

References

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci*.2017;9 [Epub ahead of print].

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease.* Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):89-106.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 12, 2017 Last Revised: February 5, 2018

Treatment of Localized (Unicentric) Castleman Disease

Surgery is the recommended treatment for people with localized Castleman disease (CD) whenever possible. Removing the abnormal lymph node(s) usually cures the disease. Symptoms such as fever and fatigue that are caused by the CD go away when the lymph node is removed. Relapses are rare.

Sometimes if the diseased area is too large to be removed by surgery, medicines such as corticosteroids or rituximab might be given first. This can shrink the tumor and make it easier to remove.

Radiation can also be used to treat localized CD, either in people who can't have surgery for some reason or if surgery cannot remove all of the disease. But radiation is not used as often as surgery as the main treatment.

Some patients with localized CD develop secondary amyloidosis, a condition in which abnormal proteins build up in the kidneys, skin, and some other organs. This protein build-up stops once the lymph node(s) affected by CD is removed.

The outlook for localized CD is very good if the affected lymph node(s) can be removed with surgery (or treated with radiation). But sometimes not all of the disease can be removed or treated safely. This doesn't necessarily mean it will continue to grow and get worse. Even partial removal may help, and the disease may not grow back.

References

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: *Hematology: Basic Principles and Practice*, 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418.

Nagubandi R, Wang Y, Dutcher JP, Rao PM. Classic case of unicentric mixed-type Castleman's disease. *J Clin Oncol*. 2013;31:e452–455

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease.* Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Sarana B, Jaal J, Tamm H, Laisaar T. Resection of unicentric interlobar Castleman disease with following adjuvant radiotherapy. *SAGE Open Med Case Rep*.2017;5:2050313X17744481.

Wong RSM. Unicentric Castleman disease. *Hematol Oncol Clin North Am*.2018;32(1):65-73.

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 12, 2017 Last Revised: February 5, 2018

Treatment of Multicentric Castleman Disease

Multicentric Castleman disease (MCD) is usually much harder to treat than localized CD. There is no standard therapy for MCD, and no single treatment works for all patients. Several types of treatment have been shown to help some patients. But because MCD is rare, it has been hard for doctors to compare different treatments against each other in clinical trials.

Surgery is used to biopsy an affected lymph node to make the diagnosis, but MCD is too widespread to remove it all with surgery or treat it effectively with radiation. Still, some people are helped by these treatments. For example, surgery is sometimes used to remove an enlarged spleen that is causing symptoms, or radiation can be used to shrink tumors in a specific area that are causing problems.

More often, doctors use treatments that can reach all parts of the body, such as corticosteroids, chemotherapy, or immunotherapy, when treating MCD. Doctors usually try one or a combination of these treatments to try to put the disease into remission. Anti-viral drugs including anti-HIV treatment may also help.

In some patients the disease shrinks or even goes away completely with treatment, at least for a time. In others, the benefit does not last long and symptoms come back once treatment is stopped. Some patients may not be helped by these drugs at all.

In people whose MCD is no longer responding to other treatments, some doctors might recommend high-dose chemotherapy followed by a stem cell transplant. There are a

few reported cases of this being successful. This is a complex, serious, and often expensive treatment, so it's important to understand what it might entail if you are considering this option. For more on this treatment, see Stem Cell Transplant for Cancer.[1]

The long-term outlook (prognosis) for people with MCD is often not as good as for people with localized CD. Treatment can often help for a time, but the disease tends to come back within a couple of years. A major concern is that people with MCD are at risk of dying from other causes, like serious infections or progression of the MCD to a fast-growing form of lymphoma that is hard to treat. (For more information about lymphoma, see Non-Hodgkin Lymphoma[2].)

The outlook for MCD tends to be worse if the person also has HIV/AIDS[3]. Even if the HIV infection is under control with drug treatment, the MCD is not likely to go away. The treatment and outlook of MCD can also be complicated by the presence of Kaposi sarcoma[4] and other AIDS-related conditions. These conditions may be less of a problem if the patient is on anti-HIV treatment.

Because MCD can be hard to treat, taking part in a clinical trial[5] of newer treatments can be a good option for some people. (See What's New in Research of Castleman Disease?[6] for a description of some newer treatments.)

Hyperlinks

1. www.cancer.org/treatment/treatments-and-side-effects/treatment-types/stem-cell-transplant.html
2. www.cancer.org/cancer/non-hodgkin-lymphoma.html
3. www.cancer.org/cancer/cancer-causes/infectious-agents/hiv-infection-aids.html
4. www.cancer.org/cancer/kaposi-sarcoma.html
5. www.cancer.org/treatment/treatments-and-side-effects/clinical-trials.html
6. www.cancer.org/cancer/castleman-disease/about/new-research.html

References

Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy. *Blood*. 2014;123(19):2924-2933.

Fajgenbaum DC, Kurzrock R. Siltuximab: A targeted therapy for idiopathic multicentric Castleman disease. *Immunotherapy.* 2016;8(1):17-26.

Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. *Blood.* 2017;129(12):1646-1657.

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: A systematic literature review. *Lancet Haematol* 2016;3(4):e163-165.

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. *Cancer Sci*.2017;9 [Epub ahead of print].

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: *Hematology: Basic Principles and Practice*, 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418.

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on January 11, 2018.

National Cancer Institute. *Castleman disease.* Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on January 11, 2018 .

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. *Ann Oncol.* 2009;20:775–779.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE,

eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 12, 2017 Last Revised: February 5, 2018

Written by

The American Cancer Society medical and editorial content team (www.cancer.org/cancer/acs-medical-content-and-news-staff.html)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

cancer.org | 1.800.227.2345

After Castleman Disease Treatment

Living Well After Treatment

For many people, completing treatment often raises questions about next steps as a survivor.

- Living With Castleman Disease

Living With Castleman Disease

For many people with Castleman disease (CD), treatment can remove or destroy the disease. Completing treatment can be both stressful and exciting. You may be relieved to finish treatment, but find it hard not to worry about the CD coming back. (When the disease comes back after treatment, it is called recurrence[1].) This is a very common concern in people with serious diseases such as CD.

For some people, CD may never go away completely[2]. These people may get regular treatments with chemotherapy[3], corticosteroids[4], or other therapies[5] to help keep the CD in check for as long as possible. Learning to live with CD as a more of a chronic disease can be difficult and very stressful. It has its own type of uncertainty.

Follow-up care

If you have completed treatment, frequent follow-up exams are very important for several years after the treatment is finished. The doctors will continue to watch you for

signs of recurrent disease, as well as for short-term and long-term side effects of treatment. It's important to report any new symptoms to the doctor right away, so that relapse or side effects can be treated.

Checkups usually include careful physical exams, imaging tests[6]such as CT scans when needed, and lab tests[7]to look for signs of CD or treatment side effects. Almost any type of treatment can have side effects. Some can last for a few weeks to months, but others can last the rest of your life.

CD can come back in some people. Multicentric CD may come back as soon as the first year after treatment. If the CD does recur at some point, further treatment will depend on what treatments you've had before, how well they worked, how long it's been since treatment, and your overall health.

Some people with multicentric CD (especially those who are HIV-positive) might develop non-Hodgkin lymphoma[8] or Kaposi sarcoma[9] at some point. These cancers can be hard to treat, so it helps to diagnose and treat them as early as possible.

Hyperlinks

1. www.cancer.org/treatment/survivorship-during-and-after-treatment/understanding-recurrence.html
2. www.cancer.org/treatment/survivorship-during-and-after-treatment/when-cancer-doesnt-go-away.html
3. www.cancer.org/cancer/castleman-disease/treating/chemotherapy.html
4. www.cancer.org/cancer/castleman-disease/treating/corticosteriods.html
5. www.cancer.org/cancer/castleman-disease/treating.html
6. www.cancer.org/treatment/understanding-your-diagnosis/tests/imaging-radiology-tests-for-cancer.html
7. www.cancer.org/treatment/understanding-your-diagnosis/tests.html
8. www.cancer.org/cancer/non-hodgkin-lymphoma.html
9. www.cancer.org/cancer/kaposi-sarcoma.html

References

Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of

cancer with healthy food choices and physical activity. *CA: A Cancer Journal for Clinicians.* 2012 Jan-Feb;62(1):30-67.

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya K S, Schwartz AL, Bandera E V, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. *CA: A Cancer Journal for Clinicians.* 2012 Jul-Aug;62(4):242–274.

See all references for Castleman Disease (www.cancer.org/cancer/castleman-disease/references.html)

Last Medical Review: January 10, 2017 Last Revised: February 7, 2018

Written by

The American Cancer Society medical and editorial content team (www.cancer.org/cancer/acs-medical-content-and-news-staff.html)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.